Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors

Anastasiia S. BoikoMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation;

Svetlana A. IvanovaMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation; ;National Research Tomsk Polytechnic University, Tomsk, Russian Federation;

Ivan V. PozhidaevMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation; ;National Research Tomsk State University, Tomsk, Russian Federation;

Maxim B. FreidinDepartment of Twin Research and Genetic Epidemiology, School of Live Course Sciences, King's College London, London, United Kingdom; ;Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation;

Diana Z. OsmanovaMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation; ;National Research Tomsk State University, Tomsk, Russian Federation;

Olga Yu FedorenkoMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation; ;National Research Tomsk Polytechnic University, Tomsk, Russian Federation;

Arkadyi V. SemkeMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation;

Nikolay A. BokhanMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation; ;National Research Tomsk State University, Tomsk, Russian Federation;

Bob WilffertGroningen Research Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, Groningen, the Netherlands; ;Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;

Anton J. M. LoonenGroningen Research Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, Groningen, the Netherlands; ;GGZ WNB, Mental health hospital, Bergen op Zoom, The NetherlandsCorrespondence[email protected]

show all

Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors

Supplemental Table

Related Research Data

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors

Supplemental Table

Related Research Data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date